We first investigated the predictive value of CTU2 in real-world immunotherapy response by incorporating data from two independent immunotherapy studies (GSE91061-melanoma; RCC-Braun_2020) (Figures 6A, B). The gene discussed is CTU2; the disease is melanoma.